Sickle Cell Disease (SCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Sickle Cell
Disease (SCD) Market Outlook
Thelansis’s “Sickle
Cell Disease (SCD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2026 To 2036” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Sickle
Cell Disease (SCD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Sickle Cell
Disease (SCD) Overview
Sickle cell disease (SCD) is an
autosomal recessive hemoglobinopathy caused by a glutamic acid to valine
substitution at position 6 of the beta-globin chain, yielding abnormal
hemoglobin S that polymerizes under deoxygenated conditions to drive erythrocyte
sickling, hemolytic anemia, and vaso-occlusion. Hallmarks include severe
episodic vaso-occlusive crises (VOCs), acute chest syndrome, stroke, and
cumulative multiorgan damage. Diagnosis is established via universal newborn
screening using hemoglobin electrophoresis or HPLC. Hydroxyurea remains the
foundational oral disease-modifying standard of care to elevate fetal
hemoglobin, supplemented by oral L-glutamine to reduce oxidative stress.
Crucially, the pharmaceutical toolkit has contracted significantly due to
safety and efficacy failures: both the polymerization inhibitor voxelotor and
the P-selectin inhibitor crizanlizumab have been completely withdrawn from
global markets. Conversely, the curative space has been fundamentally
transformed. Alongside traditional matched allogeneic stem cell
transplantation, two landmark genetic therapies are approved for severe
phenotypes: lovotibeglogene autotemcel (Lyfgenia), a lentiviral gene-addition
therapy, and exagamglogene autotemcel (Casgevy), a CRISPR-Cas9 gene-editing
platform targeting BCL11A to restore functional fetal hemoglobin. These
molecular therapies yield near-complete elimination of VOCs, radically
rewriting the long-term prognosis.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment